Alvotech SA, a global biotech company specializing in biosimilar medicines, has reported its financial results for the first half of 2025. The company achieved a net profit of $141.7 million, or $0.50 per share, a significant turnaround from the net loss of $153.5 million reported for the same period in 2024. This improvement is attributed to robust product revenue growth, favorable changes in derivative liabilities, and reduced finance costs due to capital structure optimization. The company reported a substantial increase in product revenue, reaching $204.7 million for the six months ended June 30, 2025, compared to $65.9 million in the corresponding period of the previous year. This increase was driven by the expansion of sales for AVT02 in the U.S., Canada, and Europe, as well as the launch and increased sales of AVT04. Operating profit for the period was $28.6 million, down from $43.4 million in the prior year, due to the timing of milestone-related revenue recognition. However, this was partially offset by increased product sales in key markets. Alvotech continued to invest in commercialization, regulatory progression, and pipeline development, aiming for long-term growth. The company's cash position as of June 30, 2025, stood at $151.5 million, bolstered by its operational performance and a Swedish private placement raising approximately SEK 789 million. Borrowings totaled $1,118.2 million. Alvotech remains listed on the Nasdaq Stockholm Market and continues to expand its commercial partnerships for its pipeline assets.